NSCLC

First-Line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefits in PD-L1+ NSCLC

adminpost May 17, 2023

Eftilagimod alfa (efti; IMP321) plus pembrolizumab (Keytruda) provided overall survival (OS) benefit compared with...

Osimertinib plus chemotherapy improves PFS in advanced EGFR+ NSCLC

adminpost May 17, 2023

The combination of osimertinib (Tagrisso) and platinum-based chemotherapy led to a statistically significant and...

AEGEAN Study Shows Benefit of Combination Based Immunotherapy for NSCLC

adminpost May 11, 2023

By Alice GoodmanMay 10, 2023 Patients with Treatment-naive resectable non-small cell lung cancer (NSCLC)...